CAR-T therapy: a revolution in immunotherapy for blood cancers
CAR-T cell therapy, often described as a revolution in haemato-oncology, involves collecting a patient's T lymphocytes, genetically modifying them so that they specifically recognise tumour cells, and then re-infusing them so that they destroy those cancer cells with unprecedented power and persistence. This treatment, part of the broader field of immunotherapy, has already transformed the outlook for certain aggressive lymphomas, acute lymphoblastic leukaemias and multiple myelomas that had failed other treatments, while raising complex questions about tolerability, cost, organisation of care and fair access to this innovation.
Long-term follow-up data suggest that a significant proportion of patients can achieve prolonged, possibly curative remissions, particularly with CAR-T cells targeting CD19 in B-cell malignancies, whereas anti-BCMA CAR-T cells in myeloma seem to induce responses that are often more transient, but with limited late toxicity.
At the same time, the recognition of specific toxicities such as cytokine release syndrome, ICANS neurotoxicity, prolonged cytopenias, opportunistic infections and, more recently, the risk of secondary cancers derived from the modified T cells calls for constant vigilance, long-term monitoring and continual updating of care guidelines. The rapid growth of clinical trials, with more than 1,500 studies registered worldwide, signals a profound scientific movement towards CAR-T cells that are safer, more effective, better suited to solid tumours and perhaps, tomorrow, to autoimmune diseases, while forcing health systems, notably in France and Europe, to rethink their funding models, care pathways and patient information tools.
Key points at a glance
- CAR-T cells are the patient's own T lymphocytes, modified in the laboratory to recognise a target on cancer cells, then re-infused.
- They are used mainly in certain lymphomas, acute lymphoblastic leukaemias and multiple myelomas, usually after standard treatments have failed or the disease has relapsed.
- The treatment can lead to long-lasting remissions, but it carries serious side effects (cytokine release syndrome, neurotoxicity, infections) that require follow-up in a specialist centre.
- Cost, organisation of care and fair access remain major challenges.
Health disclaimer: this article is for information only. It does not replace the advice of the haematology or oncology team caring for the patient, who alone can assess the value and risks of CAR-T treatment in a given situation.
1. Understanding CAR-T therapy: definition, general principle and place in immunotherapy
1.1. An immunotherapy based on engineering T lymphocytes
CAR-T cell therapy belongs to the large family of immunotherapies, treatments that aim to mobilise and modulate the patient's immune system to fight cancer or other diseases. More precisely, it is a personalised cell therapy in which the patient's T lymphocytes are used as the "raw material" to make a unique medicine that is then given back to them. T lymphocytes are central players in adaptive immunity, able to recognise specific antigens and destroy cells carrying those antigens through complex cytotoxic mechanisms involving perforins, granzymes and apoptotic pathways. In many blood cancers, however, tumour cells manage to escape this immune surveillance by modulating the expression of major histocompatibility complex molecules, expressing inhibitory ligands or reshaping the tumour microenvironment to create local immunosuppression.
CAR-T cells try to get around some of these escape mechanisms by equipping T lymphocytes with an artificial receptor, the chimeric antigen receptor or CAR, which lets them recognise a tumour surface antigen directly, independently of presentation by the major histocompatibility complex. This chimeric receptor combines the recognition part of a monoclonal antibody, in the form of a single-chain variable fragment (scFv), with one or more intracellular signalling domains taken from the T-cell receptor and from co-stimulatory molecules such as CD28 or 4-1BB, so as to trigger strong activation, proliferation and cytotoxic function of the modified lymphocytes when they meet their target cell. In practice, this means programming T lymphocytes to carry on their surface a kind of molecular "sword" able to bind the targeted tumour antigen and trigger a full attack signal.
This reprogramming is done in the laboratory, usually with viral vectors (lentiviral or retroviral) that insert the gene encoding the CAR into the T cells' genome, ensuring stable expression of the receptor on their membrane. Once these CAR-T cells have been produced and multiplied, they are sent back to the hospital, where they are infused into the patient after so-called "lymphodepleting" chemotherapy, intended to create an environment favourable to their expansion in the body. CAR-T therapy is thus radically different from conventional chemotherapy, which acts fairly non-specifically on rapidly dividing cells, and from monoclonal antibodies, which target tumour antigens but do not provide the same memory or dynamic capacity to expand as living lymphocytes.
In clinical practice, this immunotherapy is currently used mainly as a second-line, third-line or later treatment, in patients whose disease has resisted or relapsed after standard treatments, whether intensive chemotherapy, anti-CD20 antibodies or autologous stem cell transplantation. It is therefore a salvage option for situations with an often very poor prognosis, but it is also gradually being considered earlier in some treatment strategies, as efficacy and safety data accumulate from real-world use and randomised trials.
1.2. The main current indications: lymphoma, leukaemia and myeloma
The first CAR-T indications to obtain marketing authorisation in Europe were B-cell acute lymphoblastic leukaemia (B-ALL) in children and young adults, and diffuse large B-cell lymphoma (DLBCL), an aggressive form of non-Hodgkin lymphoma. In 2018, two medicines, Kymriah (tisagenlecleucel, Novartis) and Yescarta (axicabtagene ciloleucel, Gilead), received European marketing authorisation for these rare but serious indications, after showing significant response rates and improved 12-month survival compared with historical expectations. For DLBCL with a very short life expectancy, clinical studies showed estimated 12-month survival rates of about 40% for Kymriah and 60% for Yescarta, results considered remarkable after conventional treatments had failed. In parallel, CAR-T cells have been extended to other aggressive lymphomas, such as mantle cell lymphoma, and to refractory multiple myeloma via CAR-T cells targeting B-cell maturation antigen (BCMA).
Beyond these approved indications, clinical trials are exploring many experimental CAR-T cells across a wide range of blood cancers, including other B-cell lymphomas, chronic leukaemias, acute myeloid leukaemias and myelodysplastic syndromes, often in combination with other immunomodulating agents. A recent review of ClinicalTrials.gov registrations identified more than 1,500 CAR-T-related clinical trials, over 70% of them in haematological diseases, confirming that haematological oncology remains the core of current applications. Most of these trials are still phase I or I/II, reflecting a field still being explored, with relatively few late-phase trials but a profusion of different constructs, bispecific designs and treatment combinations.
As follow-up data accumulate, it appears that CAR-T cells targeting CD19, a surface antigen of B cells, can induce prolonged remissions in some patients with B-cell diseases, notably DLBCL and B-ALL, and are probably curative for a fraction of them. Long-term follow-up studies, beyond ten years for the first patients treated, show that these remissions can persist without major late toxicity in a significant proportion of patients, suggesting that functional CAR-T persistence and immune reconstitution can coexist in a relatively balanced way. By contrast, BCMA-targeting CAR-T cells in multiple myeloma currently seem to produce often impressive but more transient responses, with remissions that generally fade sooner, despite limited late toxicity overall. This asymmetry between CD19 and BCMA illustrates what is at stake in choosing the target antigen, but also the fundamental differences between the biology of these diseases and their bone marrow microenvironment.
1.3. A promising and closely regulated innovation in France
In France, the National Authority for Health (HAS) identified early on the potential of CAR-T cell therapies for certain refractory or relapsed blood cancers, while stressing the remaining uncertainty about their efficiency, that is, cost-effectiveness and overall budget impact on the health system. At the end of 2018, HAS issued a favourable opinion on their reimbursement, so that patients with no other treatment options could access these innovations outside the exceptional framework of temporary use authorisations, and within relatively short timeframes compared with usual procedures. In its assessment, HAS took into account not only the clinical benefits seen in studies, but also the complexity of the medical procedures involved, such as collecting T lymphocytes by leukapheresis and infusing the genetically modified cells, which were also assessed and coded within activity-based hospital funding.
However, HAS stressed the lack of robust medium- and long-term efficacy and safety data at the time of the decision, which led it to announce a later reassessment of CAR-T cells based on real-world data. To that end, it requested a dedicated registry, common to the various CAR-T medicines, to collect up-to-date information on efficacy, tolerability, quality of life and late complications, in order to confirm or adjust the initial conclusions on medical benefit. On the basis of these data and national studies, such as the analysis of the first 116 patients treated in France in five centres between 2018 and 2019, which showed one-year survival of 67% in patients with relapsed aggressive lymphoma, CAR-T therapy became firmly established, clinically and institutionally, as a major option in these situations.
This takes place within a specific organisation of care, in which CAR-T therapy is delivered only in qualified centres with haematology, intensive care, neurology and hospital pharmacy teams able to handle the technical, biological and clinical aspects of the treatment. The care pathway is carefully planned with the patient, including selection, information and informed consent, leukapheresis, cell manufacturing, hospital admission for lymphodepleting chemotherapy and infusion, then close monitoring and follow-up over several years. In this context, the French National Cancer Institute (INCa) and European partners such as the T2EVOLVE consortium are working to improve the quality of information given to patients, the clarity of consent forms and the inclusion of patients' perspectives in the rollout strategy for these therapies, in order to reconcile rapid innovation with respect for patients' rights, understanding and autonomy.
2. Immunological mechanisms of CAR-T cells: from antigen recognition to tumour destruction
2.1. Normal function of cytotoxic T lymphocytes and the anti-tumour immunity cycle
To understand what makes CAR-T therapy special, it helps to recall briefly the normal role of cytotoxic T lymphocytes (CD8+ T cells) in immune surveillance of cancer. Under normal conditions, dendritic cells and other antigen-presenting cells capture tumour antigens, often as peptides derived from proteins that are altered or overexpressed by the cancer cell, and present them to T lymphocytes via class I major histocompatibility complex molecules (MHC I). This presentation, combined with co-stimulatory signals and a pro-inflammatory cytokine environment, triggers activation of CD8+ T cells, their clonal expansion and their differentiation into cytotoxic effector cells able to recognise and specifically kill cells carrying the same antigen presented by MHC I.
The attack on tumour cells by cytotoxic lymphocytes relies on several complementary mechanisms. Activated CD8+ T cells secrete perforins that punch holes in the target cell's membrane, letting in granzymes, proteases that trigger programmed cell death cascades. They can also express molecules of the TNF superfamily, such as TRAIL, which interacts with death receptors such as DR4 and DR5 on the tumour cell to activate extrinsic apoptosis pathways. In addition, engagement of Fas (CD95) by its ligand FasL on T cells can induce the formation of a death-inducing signalling complex (DISC) that activates caspase 8, then caspase 3 and the breakdown of many key intracellular proteins, leading to apoptosis of the cancer cell. Finally, production of pro-inflammatory cytokines such as interleukin-2 (IL-2), interferon gamma (IFN-γ) and TNF-α helps strengthen the overall immune response, recruit other immune effectors and reshape the tumour microenvironment in a way that is more hostile to the tumour.
This anti-tumour immunity cycle is not always enough to control tumour growth, however. The cancer cell may lose expression of some antigens, reduce antigen presentation via MHC I, secrete immunosuppressive cytokines, recruit regulatory or myeloid suppressor cells, and overexpress immune checkpoint ligands such as PD-L1, which helps exhaust or inhibit specific T lymphocytes. Because of this "immunoediting" process, even if the immune system initially recognises tumour cells, it may gradually become unable to eliminate them, allowing the disease to progress. Conventional immunotherapies, such as checkpoint inhibitors, try to release these brakes by blocking PD-1, CTLA-4 or other inhibitory pathways, while monoclonal antibodies target specific tumour antigens to mark cells for destruction. CAR-T cells take a more radical approach by directly reprogramming T effector cells so that they carry a receptor that recognises the tumour antigen directly, independently of MHC presentation.
2.2. Architecture of a chimeric antigen receptor (CAR)
The chimeric antigen receptor that gives T lymphocytes their tumour specificity in CAR-T therapy is a sophisticated molecular construct combining elements of antibodies and T-cell receptors in a single membrane protein. At the extracellular end, the CAR has a recognition domain derived from the variable region of a monoclonal antibody against the targeted antigen, typically CD19 for B-cell malignancies or BCMA for multiple myeloma. This variable region is configured as a single-chain variable fragment, scFv, which links the variable domains of the antibody's heavy and light chains with a short flexible peptide, so as to preserve the original antibody's recognition specificity and affinity.
The scFv domain is connected to a hinge domain and a transmembrane domain that anchor the CAR in the T cell's membrane and partly determine the distance and orientation of the scFv relative to the target cell surface, which can influence the effectiveness of the immunological synapse and signalling. Inside the T cell, the CAR first carries a primary signalling domain derived from the CD3ζ complex, the central signal transduction element of the natural T-cell receptor; this domain contains ITAM motifs that, once phosphorylated, trigger the classic T-cell activation cascade. Second- and third-generation CARs add to this CD3ζ domain one or more co-stimulatory domains, typically CD28 or 4-1BB, sometimes OX40, to amplify survival, proliferation and differentiation signals towards effector and memory cells.
The combination of these domains gives CAR-T cells very powerful signalling capacity when the scFv binds the target antigen on the tumour cell. Unlike unmodified T lymphocytes, CAR-T cells do not need to recognise a peptide presented by MHC, nor to receive co-stimulatory signals via natural ligands such as CD80 or CD86; co-stimulation is "hard-wired" into the very structure of the CAR, so that simple binding of the scFv to the antigen is enough to trigger full activation. This activation results in rapid cytokine secretion, increased expression of cytotoxic molecules, clonal expansion of the CAR-T cells and the formation of stable immunological synapses with tumour cells, leading to their repeated destruction.
This signalling power is a double-edged sword. On the one hand, it produces impressive clinical responses in patients whose tumours had resisted very intensive treatments, as confirmed by the response and survival rates seen in the first cohorts of patients with DLBCL or B-ALL after treatment failure. On the other, it can generate massive cytokine production, notably IL-6, IFN-γ and TNF-α, which shows clinically as cytokine release syndrome (CRS), a sometimes serious side effect considered the most frequent specific toxicity of CAR-T cells. CAR design, the choice of co-stimulatory domains and the density of CAR expression on the T-cell surface are therefore crucial parameters in trying to balance anti-tumour efficacy against acceptable tolerability.
2.3. How CAR-T cells act in the body: cytotoxicity, cytokines and immune remodelling
Once infused into the patient after lymphodepletion, CAR-T cells spread through the blood, the bone marrow and tumour sites, where they can encounter the target antigen on cancer cells. Binding of the scFv to the tumour antigen leads to formation of an immunological synapse and clustering of the CAR, which triggers phosphorylation of the CD3ζ ITAMs and activation of intracellular signalling cascades involving ZAP-70, PLCγ, PKC, NF-κB, NFAT and AP-1. This activation rapidly leads to production of pro-inflammatory cytokines such as IL-2, IFN-γ and TNF-α, as well as other mediators that recruit innate immune cells, intensify local inflammation and modulate angiogenesis and tumour cell survival.
On the cytotoxic side, CAR-T cells release dense granules containing perforin and granzymes, which perforate tumour cell membranes and trigger apoptosis via extrinsic and intrinsic pathways. They can also express TNF superfamily ligands such as TRAIL, which interact with death receptors on cancer cells (DR4, DR5) to activate initiator caspases, notably caspase 8, then caspase 3, leading to DNA fragmentation, chromatin condensation and programmed cell death. Engagement of the Fas/FasL pathway is another way CAR-T cells can kill target cells, through formation of the DISC complex and activation of the same apoptotic cascades.
The destruction of tumour cells in turn releases additional antigens, which can be taken up by dendritic cells and presented to other, unmodified T lymphocytes, potentially contributing to a secondary cycle of anti-tumour immunity involving the body's own effectors. In this way, beyond its direct action, CAR-T therapy may partly reactivate natural immune surveillance and broaden the diversity of T-cell responses against the tumour. The persistence of CAR-T cells in the body, sometimes observed for years in some patients, maintains lasting immune pressure on residual tumour cells, which may help prevent or delay relapse.
The same set of mechanisms, however, explains much of the acute and subacute toxicity of CAR-T cells. Massive cytokine release can cause high fever, low blood pressure, low blood oxygen and dysfunction of vital organs, making up the picture of CRS, which most often occurs in the first two weeks after the cells are infused. The specific neurological disorders grouped under the term ICANS are probably linked to a combination of factors, including entry of cytokines and immune cells into the central nervous system, disruption of the blood-brain barrier and direct or indirect effects on neurons and glial cells. Finally, depletion of normal B cells, a consequence of CD19 expression on these cells, together with lymphopenia and prolonged cytopenias linked to immune-mediated effects of CAR-T cells, increases the risk of opportunistic infections and late haematological complications.
3. The patient pathway for CAR-T treatment: from selection to re-infusion and follow-up
3.1. Selection and eligibility: medical and organisational criteria
A patient's path towards CAR-T therapy begins with a selection phase, during which the medical team assesses whether the disease profile, general health and other conditions make the treatment both appropriate and feasible. This step is crucial, because CAR-T therapy is reserved for well-defined situations, typically blood cancers that have relapsed or are refractory after several lines of standard treatment, and because it carries significant risks requiring the capacity for monitoring and rapid intervention. Eligibility criteria generally cover the type of cancer, its stage, response or resistance to previous treatments, the patient's age, their functional status (for example performance status) and specific biological and imaging parameters.
The medical literature sets out in tables the main laboratory tests and imaging needed to select patients, including blood counts, kidney and liver function, disease markers and CT or PET scans to assess tumour burden. Severe comorbidities, particularly cardiac, pulmonary or neurological, may rule out or complicate CAR-T administration because of the risk of severe CRS or ICANS, while some ongoing or uncontrolled infections must be stabilised first. In France, only qualified centres can offer this treatment, which also brings organisational and geographical considerations into selection, especially for patients living far from expert centres.
Once CAR-T treatment is being considered, the multidisciplinary team discusses the case at a tumour board meeting and informs the patient thoroughly about the expected benefits, uncertainties, risks, stages of the pathway and logistical constraints. Informed consent is then obtained, within an increasingly structured framework, as shown by the work of INCa and the European T2EVOLVE project, which have developed a new consent form format designed to be clearer and more accessible, meeting regulatory requirements while making it easier for patients to understand. This document sets out the aims of the trial or treatment, the potential benefits, the specific risks, the course of hospital stays and the follow-up, so that the patient can make a genuinely informed decision.
3.2. Leukapheresis and manufacturing of CAR-T cells
The first technical step of treatment is collecting T lymphocytes from the patient's blood, through a procedure called leukapheresis or cytapheresis. In practice, the patient is connected to an apheresis machine that draws blood, separates its components by centrifugation, collects the T-cell-rich fraction in a bag and returns the rest of the blood to the patient. The procedure usually takes a few hours and is done as a day case or short stay, under nursing and medical supervision, with monitoring of vital signs and prevention of apheresis-related complications such as electrolyte imbalances or low calcium caused by the anticoagulants used.
The collected T lymphocytes are then checked at the hospital, notably for viability and profile, and sent to a specialised laboratory, often abroad, in the United States or Europe, to be genetically modified. Manufacturing of CAR-T cells takes several weeks, typically four to six, during which the laboratory introduces the CAR gene into the T lymphocytes using a viral vector or another gene transfer technology, then grows and multiplies the modified cells until there are enough for infusion. During this manufacturing phase, the patient's condition may change, which sometimes requires so-called "bridging" treatments to stabilise the disease, such as maintenance chemotherapy, antibodies or other targeted agents.
In practice, the time between leukapheresis and re-infusion of the CAR-T cells depends on the type of product, logistics and manufacturing constraints, ranging from three to five weeks or longer in some cases. During this time, the patient stays in contact with the medical team, which monitors the disease, adjusts the bridging treatment and prepares the hospital admission for the infusion. Once the CAR-T cells have been made and sent back to the hospital, they are stored under controlled conditions until the time of injection, following strict traceability and pharmaceutical safety protocols.
3.3. Lymphodepleting chemotherapy and CAR-T infusion
Before the CAR-T cells are injected, the patient receives a short course of so-called lymphodepleting chemotherapy, which aims to reduce the number of circulating lymphocytes and create an immune environment favourable to CAR-T expansion after infusion. This lymphodepletion, often based on fludarabine and cyclophosphamide, helps CAR-T cells occupy immune niches, increases their access to growth signals and reduces competition with the body's own lymphocytes. This phase usually lasts three days, in hospital, with close monitoring of laboratory and clinical parameters, because it can itself cause cytopenias, nausea, fatigue or temporary infection risks.
The CAR-T infusion takes place after this chemotherapy, in a short time, often as a single infusion, which is the central act of the treatment. Although the infusion itself usually goes without major immediate incident, it marks the start of a period of intensive monitoring, because the specific side effects, notably cytokine release syndrome and ICANS neurotoxicity, usually occur in the following days. Expert centres recommend a hospital stay of two to three weeks for this phase, covering lymphodepletion, infusion and post-infusion monitoring, with a team on hand to react quickly to any sign of toxicity.
In the days after the infusion, the medical team watches closely for fever, low blood pressure, breathing problems, pain, skin rash or organ involvement, which may signal emerging CRS, and also monitors neurological status, speech, handwriting and consciousness, to detect ICANS neurotoxicity early. According to guidelines, monitoring is particularly focused between the tenth and fifteenth day after injection, which corresponds to a period of maximum risk for these complications. If there are no significant side effects, the patient may go home from the tenth day, provided they live or stay less than an hour from the centre, so they can return quickly if worrying symptoms appear.
3.4. Short-, medium- and long-term follow-up
After the initial hospital phase, follow-up of patients treated with CAR-T cells continues in the short term with specialist consultations, blood tests and imaging (CT, PET scan or bone marrow assessments) to measure tumour response and tolerability. A first reassessment is often done one month after infusion, with imaging to see whether the tumour has shrunk, stabilised or progressed, and to gauge how deep the response is, complete or partial. This assessment comes with a detailed clinical examination, evaluation of immunological, haematological and biochemical parameters, and a discussion of the patient's perceived quality of life.
After that, regular consultations are scheduled at two, three, six, nine and twelve months, then over several years, with tests adapted to the disease and risk profile, to monitor both the course of the disease and any late side effects. Specialist centres plan five years of follow-up for patients treated with CAR-T cells, with tests focused on monitoring infections, prolonged cytopenias, hypogammaglobulinaemia (when B cells are depleted) and signs of secondary cancers. Long-term follow-up data, notably for CD19-targeting CAR-T cells, show that late toxicities are often limited, apart from prolonged B-cell depletion requiring immunoglobulin infusions to prevent infections, which follow-up protocols take into account.
Health authorities have recently warned about secondary malignancies arising from T lymphocytes, including CAR-positive tumours, occurring weeks to several years after CAR-T therapies directed against CD19 or BCMA, leading to a recommendation for lifelong monitoring of patients to detect such complications. These observations, although rare, show that follow-up cannot stop after a few years, and that a registry and prolonged vigilance are needed to fully understand the safety profile of CAR-T cells. In addition, assessment of quality of life, which appears broadly favourable in studies of several hundred patients with blood cancers treated with CAR-T cells, remains an important part of follow-up, to reconcile clinical efficacy with the functional and psychosocial impact of the treatment.
4. Clinical efficacy and expected benefits: remissions, survival and quality of life
4.1. Results in aggressive lymphomas and acute lymphoblastic leukaemias
The strongest data on the efficacy of CAR-T therapies concern aggressive B-cell lymphomas, particularly DLBCL, and B-ALL in children and young adults, the first indications to receive European marketing authorisation. In these diseases, patients who are candidates for CAR-T cells have often run out of options after two or more lines of standard treatment, including intensive chemotherapy and sometimes stem cell transplants, with a very poor prognosis. The clinical studies supporting the authorisation of Kymriah and Yescarta showed significant complete response rates and 12-month survival rates well above historical expectations for this population.
In patients with DLBCL whose lives were at immediate risk, estimated 12-month survival was reported to be about 40% for Kymriah and 60% for Yescarta, figures that represent a substantial improvement over cohorts receiving only conventional treatment in the same situation. A French national analysis of the first 116 patients treated with CAR-T cells between 2018 and 2019 in five centres showed one-year survival of 67%, confirming at population level the potential impact of these therapies in relapsed aggressive lymphoma. Although these results must be interpreted with the selection bias in mind (patients had to be "fit" enough to receive CAR-T cells), they provide a solid basis for regarding these immunotherapies as major options in these indications.
In B-ALL in children and young adults, CAR-T therapy, notably tisagenlecleucel, has achieved high complete remission rates in patients who had exhausted almost all other options, sometimes after failure of an allogeneic stem cell transplant. The remissions induced in these cohorts, together with the possibility of long-lasting CAR-T persistence, have changed the treatment paradigm for these leukaemias, opening up hope of prolonged survival in situations that were previously almost desperate. HAS assessments awarded these therapies an improvement in medical benefit rating (ASMR) of III or IV in the various indications, formally recognising their therapeutic contribution while still requiring additional long-term data.
4.2. Multiple myeloma and other blood cancers: transient but significant responses
In multiple myeloma, BCMA-targeting CAR-T cells have shown very high response rates, with large proportions of patients reaching complete or near-complete remissions in extremely refractory disease. However, follow-up data indicate that these remissions tend to be more transient than those seen with anti-CD19 CAR-T cells in B-cell lymphomas, with a shorter median duration of response and more frequent relapses. This difference may be explained by the particular biology of myeloma, which develops in a complex bone marrow microenvironment, by the plasticity of tumour clones and by specific escape mechanisms, including loss of BCMA expression or the emergence of antigen variants.
Nevertheless, even if these therapies are not yet clearly curative for a significant fraction of patients, they often provide deep remissions and prolong survival, while offering an alternative where standard lines have failed, which justifies their growing use in treatment strategies for very advanced myeloma. In other blood cancers, such as mantle cell lymphoma, CAR-T cells targeting CD19 or other antigens have also shown substantial response rates, with prolonged remissions in some patients, although data remain more limited and often come from small series or early-phase studies.
The overall analysis of CAR-T clinical trials, covering more than 1,500 registered studies, shows that most of the indications explored are haematological diseases, confirming that this is where clinical efficacy is currently best documented and most promising. Late-phase trials remain relatively rare, which means that many indications, especially the rarest, still rely on preliminary, often non-comparative evidence, calling for caution and oversight as they spread.
4.3. Prospects in solid tumours and new indications
Beyond blood cancers, a growing share of CAR-T clinical trials concerns solid tumours, which now account for nearly a quarter of registered studies, with a 170% increase in the number of trials targeting these diseases between 2020 and 2024, far outpacing growth in haematological cancers. The targeted tumours include cancers of the liver, gallbladder and pancreas, but also of the oesophagus, stomach and colon, urogenital cancers such as kidney, bladder or prostate cancer, and tumours of the breast, thyroid, nasopharynx, uterus and ovaries. The CAR-T cells used in these trials target a variety of antigens, including TAG72, B7-H3, MUC1, MUC16 and others, sometimes with a dual-target approach to overcome antigen heterogeneity and escape mechanisms.
Results in solid tumours are so far more modest than in blood cancers, reflecting the challenges specific to these diseases, notably the density of the tumour microenvironment, physical and immune barriers, strong antigen heterogeneity and the risk of off-tumour toxicity if the targeted antigens are expressed on healthy tissue. Trials are exploring many approaches to improve efficacy, combining CAR-T cells with checkpoint inhibitors, oncolytic viruses, targeted radiotherapy or agents that modify the microenvironment, or designing CARs with modular domains or activation control systems.
In addition, a small number of trials are investigating CAR-T cells in non-malignant diseases, notably autoimmune conditions, by targeting specific disease-causing cell populations, which opens up new conceptual perspectives for these therapies. Although these indications are still marginal, they show the potential of CAR-T cells as a platform for immune engineering well beyond cancer, provided their safety and reversibility can be mastered.
4.4. Quality of life and comparison of administration settings
Beyond tumour responses and survival, patient-reported quality of life is a key indicator of the overall benefit of CAR-T therapies. A major study of 389 adult patients with blood cancers treated with CAR-T cells, presented by INCa and published in Blood Advances, showed that quality of life reported after these treatments is broadly favourable, despite the potential toxicity involved. Once past the acute toxicity phase, patients often describe an improvement in their overall functioning, their symptoms and their ability to resume some activities, which shows the transformative potential of these therapies in situations with a very poor prognosis.
Another aspect of quality of life is where CAR-T therapy is given. Traditionally, these treatments are given in hospital, with a prolonged stay for infusion and toxicity monitoring. However, recent studies of outpatient administration have shown that CAR-T cells can be infused on an outpatient basis, with close monitoring and unplanned admissions if needed, while achieving comparable results in terms of safety, efficacy and quality of life. In a review of eleven studies reporting data for both outpatient and inpatient care, overall response rates were similar, at 80 to 82% for outpatients and 72 to 80% for inpatients, and toxicity rates were comparable, provided patients met strict selection criteria.
Studies also indicate that patients treated as outpatients show quality-of-life improvements similar to those treated in hospital, while reducing the overall hospital burden and time spent in hospital. Outpatient care should, however, be reserved for patients whose disease, general health and practical circumstances allow close follow-up and rapid management of complications, which is not the case for all CAR-T candidates. If confirmed and generalised, this shift could help reduce the emotional and practical burden of long hospital stays, while lowering the overall cost of treatment for health systems.
5. Toxicities and risks of CAR-T therapy: CRS, neurotoxicity, cytopenias, infections and secondary cancers
5.1. Cytokine release syndrome (CRS)
Cytokine release syndrome, often abbreviated CRS, is the most frequent and emblematic specific toxicity of CAR-T cell therapy. It occurs when massive activation of CAR-T cells and associated immune cells causes a large release of pro-inflammatory cytokines, notably IL-6, IL-10, IFN-γ and TNF-α, resulting in acute systemic inflammation. Clinically, CRS shows as fever, sometimes very high, muscle and joint pain, headaches, skin rashes and signs of vital organ dysfunction such as kidney, liver, respiratory or heart failure.
The syndrome most often appears during the first two weeks after CAR-T injection, coinciding with the peak expansion of CAR-T cells and the peak of cytokine release. Its severity ranges from mild forms, limited to fever and moderate general symptoms, to severe forms with low blood pressure requiring vasopressors, low oxygen requiring ventilation, or even multi-organ failure that can be life-threatening. Studies show that without rapid, appropriate management, CRS can become severe or fatal, which is why close monitoring during the first days after infusion is mandatory, in hospital or in a very closely supervised outpatient setting.
Management of CRS is based on grading severity and stepwise interventions. Moderate forms can be handled with symptomatic treatment, fluids and monitoring, while more severe forms require anti-IL-6 or anti-IL-6 receptor antibodies such as tocilizumab, with or without corticosteroids. These agents target the central role of IL-6 in CRS and often control the syndrome without seriously compromising the anti-tumour efficacy of the CAR-T cells, although the balance between controlling toxicity and preserving the immune effect is delicate. Guidelines from medical societies and national authorities incorporate these treatment strategies, with management algorithms specifying at what stage these targeted treatments should be introduced.
5.2. ICANS neurotoxicity: symptoms, diagnosis and treatment
The second most frequent specific side effect of CAR-T cells is neurotoxicity, grouped under the term ICANS, for "immune effector cell-associated neurotoxicity syndrome". ICANS can occur alone or together with CRS, but it often appears after CRS has partly or fully resolved, suggesting partly distinct mechanisms, although linked to the state of immune activation and to the permeability of the blood-brain barrier. Neurological symptoms usually develop a median of about five days after CAR-T infusion, but may be delayed by up to three weeks in roughly 10% of patients, which calls for prolonged vigilance.
The clinical manifestations of ICANS vary widely. They range from mild, rapidly reversible problems, such as slight changes in consciousness, disorientation, speech difficulties, deteriorating handwriting or tremor, to more severe forms that may include seizures, motor or sensory deficits, visual disturbances and, in the most serious cases, coma. In France, neurology teams have compiled the neurological toxicities seen in several dozen patients treated with CAR-T cells, which has helped better characterise the frequency, clinical presentation and outcome of these complications and inform their management.
Diagnosis of ICANS relies above all on clinical assessment, structured by the ASTCT grading system, which grades the severity of neurological symptoms and guides treatment decisions. Additional tests such as an electroencephalogram, brain MRI or lumbar puncture may be done to rule out other causes, such as infection, brain metastasis, stroke or a primary epileptic seizure. As a rule, neurological symptoms are short-lived, lasting around five days, provided that the appropriate treatment, based mainly on high-dose corticosteroids, is given promptly.
First-line treatment of ICANS is corticosteroids, often dexamethasone, adjusted to the severity of symptoms and how they evolve. Unlike in CRS, anti-IL-6 antibodies have not shown the same specific efficacy in ICANS, suggesting more complex disease pathways involving other cytokines, vascular disturbances or direct interactions between immune cells and central nervous system structures. Management may also include anti-epileptic drugs for seizures, intensive care monitoring and supportive measures to protect the airway, heart function and metabolic status.
5.3. Cytopenias, infections and B-cell aplasia
CAR-T therapies are frequently accompanied by cytopenias, that is, reduced numbers of blood cells, including leucopenia, neutropenia, thrombocytopenia and sometimes pancytopenia, which may be linked to lymphodepletion, CRS, immune activation or prolonged immune-mediated effects. In some cases, prolonged immune-mediated pancytopenia can occur, requiring specific management and long-term monitoring to prevent bleeding or infectious complications. Cytopenias expose the patient to a higher risk of infection, which, combined with the B-cell aplasia induced by CD19-targeting CAR-T cells, creates conditions favouring opportunistic infections and serious infectious complications.
B-cell aplasia, which results from the destruction of normal CD19-expressing B cells as well as tumour cells, leads to hypogammaglobulinaemia, a drop in serum immunoglobulins, which are essential for defence against bacterial and viral infections. This hypogammaglobulinaemia can be prolonged or even persistent, requiring regular infusions of polyvalent immunoglobulins to make up the shortfall and reduce the risk of infection. Recommendations include anti-infective prophylaxis, appropriate vaccinations and regular monitoring of serum IgG to adjust the frequency of infusions.
Infections can occur at different times after CAR-T therapy. In the acute phase, they may be promoted by neutropenia and CRS, and include pneumonia, sepsis or opportunistic infections. In the longer term, B-cell aplasia and prolonged lymphopenia can lead to latent viral infections, herpesvirus reactivations or repeated bacterial infections. Health authorities and consortia such as T2EVOLVE have produced information resources, including explanatory videos on infection risks after CAR-T therapy, to make patients and carers aware of these risks and of prevention measures.
5.4. Secondary cancers and other late effects
An emerging concern in the toxicity profile of CAR-T cells is the risk of secondary malignancies derived from the modified T lymphocytes, including CAR-positive tumours, seen weeks to several years after treatment. Health authorities, such as France's ANSM, have flagged this risk for CAR-T cell therapies directed against CD19 or BCMA, and have recommended lifelong monitoring of patients to detect secondary cancers. These tumours, rare but potentially serious, raise questions about the genomic stability of modified T cells, the risk of insertional mutagenesis from viral vectors, and the very long-term impact of these therapies on cancer development.
Long-term data on CD19-targeting CAR-T cells indicate, however, that for most patients late toxicities remain limited, apart from B-cell aplasia and prolonged cytopenias, and that a substantial proportion of patients remain in prolonged remission without serious complications, supporting the idea that these therapies can be durable and relatively safe for a subgroup of patients. For BCMA-targeting CAR-T cells, late toxicities also seem limited, with an acceptable overall tolerability profile, even if remissions are shorter.
Other late effects, such as endocrine, autoimmune or metabolic disorders, still need to be explored, because follow-up data beyond ten years are still rare and mainly concern the first waves of patients with B-cell cancers treated in pioneering centres. Real-world registries, requested by HAS and set up in various countries, will be essential to better characterise these risks, adapt monitoring recommendations and inform patients and their families precisely.
6. Organisation of care, cost and sustainability: the French case and international issues
6.1. Qualified centres, a structured pathway and the role of institutions
CAR-T cell therapy can only be offered in highly specialised hospitals with haematology, intensive care, neurology and hospital pharmacy facilities, and an organisation able to manage the logistical, biological and clinical aspects of these treatments. In France, only certain qualified centres deliver this therapy, with a precisely organised care pathway governed by national and international protocols. The pathway includes initial assessment, a collective decision, information and consent, leukapheresis, shipping the cells to the laboratory, management of bridging treatments, lymphodepletion, infusion and post-infusion monitoring, then long-term follow-up, with close coordination between the various departments and professionals involved.
Institutions such as HAS, INCa and European agencies play a key role in overseeing these therapies, assessing their efficacy, safety, cost and impact on health systems, and issuing recommendations on their indications, reimbursement and monitoring. INCa, for example, takes part in the European T2EVOLVE project, which focuses on patient involvement, simpler consent procedures and faster research and access to CAR-T therapy in Europe, highlighting the need for clear, complete information so that patients understand the aims, benefits and risks of trials and treatments.
Coordination with regulators and manufacturers is also essential, particularly regarding the manufacture of CAR-T cells, which must meet strict standards of quality, traceability and biosafety, and often takes place in laboratories abroad. Transport, storage and infusion circuits, as well as quality assurance procedures, must be rigorously established to prevent errors and contamination, and to ensure that each patient receives the product intended for them, within the required timeframe.
6.2. Hospital costs, efficiency and economic models
CAR-T therapies are expensive interventions, both in terms of the price of the product itself and the cost of hospital stays, associated tests and management of toxicities. In France, a study of the hospital cost of these therapies showed that adopting CAR-T cells leads to an extra cost for the hospital of around €6,582 per patient compared with standard treatments, and that the cost of an index hospital stay ranges from about €32,677 to €68,484, depending on the characteristics of the patient and the disease. These figures reflect the complexity of the care pathway, including leukapheresis, prolonged hospital stays for lymphodepletion and infusion, intensive care monitoring in case of CRS or ICANS, and imaging and follow-up consultations.
HAS highlighted the uncertainty about the efficiency of these products, that is, the relationship between their cost and the health gains obtained, and assessed the cost-effectiveness and budget impact of these treatments, taking into account improvements in survival, quality of life and potential savings from fewer other hospital stays or procedures. It nevertheless issued a favourable opinion on reimbursement, considering that for patients with no other options the clinical benefit justifies these costs, while requesting regular real-world data to refine these analyses.
Internationally, work on outpatient CAR-T administration has shown that the costs associated with the therapy are generally lower when it is delivered on an outpatient basis rather than as a full hospital stay, while maintaining similar results for safety, efficacy and quality of life. In several studies, post-infusion costs were markedly lower for outpatients, with total costs sometimes two to four times lower than for inpatients, hospital costs for inpatients being estimated at $62,000 to $96,000, compared with $16,000 to $38,000 for outpatients. These data suggest that for selected patients, outpatient care could be a way to reduce the economic burden of CAR-T cells without sacrificing clinical results, which may interest health systems facing tight budgets.
6.3. Sustainability and fair access
The sustainability of CAR-T therapies for health systems and fair access for patients are central to current debates on these innovations. The high costs of the product, hospital stays and long-term follow-up, combined with the need for highly specialised centres, can create geographical and socio-economic disparities, with easier access for some patients than others depending on where they live, their insurance coverage and the capacity of payers to cover these expenses. In France, the HAS reimbursement decision and the organisation of the therapy in qualified centres aim to ensure relatively fair access, but the concentration of care in a few centres and the need for patients to travel, sometimes far from home, are obstacles for some.
Economic models for funding these therapies are also under discussion, with proposals for outcome-based payment (value-based pricing), risk-sharing mechanisms between manufacturers and insurers, and conditional reimbursement schemes that account for initial uncertainty about long-term efficacy. The real-world registries requested by the authorities will make it possible to better estimate the durability of remissions, the frequency of relapses, the late toxicity profile and quality-of-life gains, which can feed into discussions on the most appropriate economic models for these therapies.
Worldwide, the multiplication of clinical trials, with more than 1,500 studies under way, signals enormous interest in CAR-T cells, but also a likely diversification of products, targets and indications, which could eventually moderate their costs and encourage more accessible therapies. Access in low-resource countries remains a crucial issue, however, as the logistical complexity and cost of these treatments currently limit their use to well-equipped hospitals, mainly in North America, Europe and parts of Asia.
7. Current research and technological innovation: towards safer, more effective and broader CAR-T cells
7.1. Diversifying targets and CAR generations
Research on CAR-T cells is advancing rapidly, as shown by the number and diversity of registered clinical trials, which exceed 1,500 studies covering a wide range of antigen targets, diseases and treatment combinations. First-generation CARs have gradually been replaced by second- and third-generation CARs incorporating co-stimulatory domains such as CD28, 4-1BB or OX40 to improve the persistence, proliferation and function of the modified T cells. Fourth-generation CARs, sometimes called TRUCKs (T cells redirected for universal cytokine killing), include modules able to secrete cytokines or immunomodulating agents at the tumour site, to reshape the microenvironment and overcome immune barriers.
Antigen targets are also diversifying: beyond CD19 and BCMA, antigens such as CD22, CD123 and CD33 in blood cancers, and antigens such as TAG72, B7-H3, MUC1, MUC16 and others in solid tumours. Trials are also exploring bispecific or multispecific CARs, which can recognise two or more antigens, to reduce the risk of escape through loss of a single antigen and to improve selectivity for tumour cells expressing combinations of markers. A recent analysis identified more than 300 dual-target CAR-T trials, most in blood cancers but a substantial proportion in solid tumours, showing growing interest in this approach.
These innovations aim to improve anti-tumour efficacy, extend the duration of responses and reduce toxicity by targeting tumour cells more precisely and fine-tuning intracellular signalling. They do, however, bring additional challenges in design, manufacturing and regulation, because constructs become more complex and the risks of immune dysregulation or off-target toxicity must be carefully assessed.
7.2. Allogeneic, controllable and inhibition-resistant CAR-T cells
Another important line of research concerns allogeneic CAR-T cells, that is, modified T cells from healthy donors rather than the patient, which are then adapted to avoid rejection or graft-versus-host disease. These "off-the-shelf" products could eventually shorten the time between the treatment decision and infusion, by avoiding leukapheresis and personalised manufacturing, which would be particularly useful for patients whose disease progresses very quickly. Allogeneic CAR-T cells nevertheless require additional modifications, for example with genome editing techniques such as CRISPR-Cas9, to remove the native T-cell receptors responsible for allogeneic reactions, adding further layers of technological and regulatory complexity.
"Controllable" or "switchable" CAR-T cells are also in development, allowing the modified cells to be switched on or off by external signals, small molecules or split-domain systems, in order to modulate the strength of the response and reduce acute toxicities. These approaches could give clinicians extra room for manoeuvre in managing CRS or ICANS, by tempering CAR-T activity while preserving the long-term anti-tumour effect.
In addition, CAR-T cells resistant to inhibition by the tumour microenvironment are being studied, incorporating modules that block PD-1, CTLA-4 or other immune checkpoints, or that secrete factors able to neutralise immunosuppressive cytokines or reprogram macrophages and myeloid suppressor cells. These innovations are especially important for solid tumours, where the microenvironment plays a central role in resistance to immunotherapies.
7.3. Combination with other treatments and new indications
Research is also exploring synergies between CAR-T cells and other treatment modalities, such as immune checkpoint inhibitors, monoclonal antibodies, targeted agents, radiotherapy and oncolytic viruses. Some trials, for example, combine anti-CD19 CAR-T cells with anti-PD-1 drugs to boost T-cell activity in B-cell lymphomas, or anti-BCMA CAR-T cells with anti-CD38 agents in myeloma, to target different components of the tumour clone. The idea is to take advantage of the complementary effects of these therapies while watching for cumulative toxicity and excessive immune dysregulation.
Indications beyond cancer, notably certain autoimmune diseases, are also being explored, with CAR-T cells targeting disease-causing lymphocyte subsets, or regulatory CAR-T cells designed to modulate the immune response. These approaches rest on the idea that T-cell engineering can be used not only to destroy tumour cells but also to reprogram dysregulated immune responses in diseases such as lupus, multiple sclerosis or rheumatoid arthritis. These applications remain experimental but show the conceptual flexibility of CAR-T cells as tools for immune engineering.
In this context, the active involvement of national institutions, international consortia and patient organisations, as in the T2EVOLVE project, is essential to oversee these innovations, ensure responsible rollout and include patients' perspectives in setting priorities and designing trials.
8. Ethics, patient information and societal perspectives
8.1. Informed consent and understanding the risks
The scientific complexity, significant risks and high costs of CAR-T therapies raise important ethical issues, particularly regarding patient information, informed consent and resource allocation. Patients who are candidates for CAR-T cells are often in highly vulnerable situations, with very advanced disease, hopes pinned on an innovative therapy presented as "revolutionary", and an ability to weigh risks that may be affected by the emotional context. It is therefore essential that the information provided is clear and complete, covering the expected benefits, the uncertainties, the risks of acute and late toxicity, including CRS, ICANS, infections, cytopenias and secondary cancers, as well as the logistical and organisational constraints of the treatment.
The T2EVOLVE project, in which INCa takes part, has developed a new informed consent form format, together with patients, patient organisations and European bodies, to make these documents more readable and accessible while meeting regulatory requirements. This format highlights the key information and explains the aims of the trial or treatment, the potential benefits, the risks, the constraints and the alternatives, so as to allow a genuinely informed decision. Such an approach is particularly important for CAR-T therapies, where the patient has to take in notions of genetic engineering, complex immune risks and long-term follow-up, which can be difficult without explanations suited to a non-specialist audience.
8.2. Distributive justice and resource allocation
Because of their high cost and highly specialised nature, CAR-T therapies raise questions of distributive justice in the allocation of health resources. Public systems must decide how far they are willing to invest large sums to treat a relatively small number of patients, often in rare indications, while respecting the principle of equal access and avoiding imbalances with other public health needs. Efficiency analyses, which try to quantify the relationship between the cost of CAR-T cells and the gains in quality-adjusted life years, inform these decisions, but they cannot fully capture the human and social dimensions, notably the impact of a long remission when no other options remain.
Conditional reimbursement or risk-sharing mechanisms have been proposed for some expensive health technologies, including CAR-T cells, linking part of the payment to real-world results, which could encourage manufacturers to optimise patient selection and product design. Implementing these models is complex, however, as it requires reliable data collection systems, agreed outcome criteria and the capacity of insurers and institutions to manage dynamic, sophisticated contracts.
8.3. Public perception of the therapy and patient support
CAR-T therapy holds a special place in the medical and public imagination, often presented in the media as a "revolution" or a "miracle" therapy for certain blood cancers. Such portrayals can fuel very high expectations among patients and their families, sometimes out of step with reality: CAR-T cells remain reserved for specific indications, carry significant risks and offer no guarantee of cure, even if their results can be spectacular for some. It is therefore important that health professionals, institutions and the media communicate responsibly, highlighting real progress but also the limits, uncertainties, side effects and conditions of access, so that hope does not turn into illusion.
Supporting patients through the CAR-T pathway requires particular attention to psychological, social and practical aspects. The treatment involves long hospital stays, travel sometimes far from home, periods of uncertainty about the response and sometimes lengthy recovery, which can affect working, family and social life. Care teams therefore need to include psychologists, social workers and mediators to support patients and their loved ones, help them cope with stress, organise daily life around the treatment and deal with possible disappointment if the therapy does not deliver the hoped-for results.
Finally, patient participation in debates on regulation, access, care and research is essential to ensure that public policy and scientific priorities take into account the needs, preferences and experiences of those directly affected. Initiatives such as the T2EVOLVE Working Group of Patients and Caregivers illustrate this desire to give patients a voice in the governance of CAR-T therapies, which is particularly relevant for innovations that touch on life, death, immune identity and the acceptance of long-term risks.
Conclusion
CAR-T cell therapy is today one of the most striking innovations in haematology and immunotherapy, combining genetic engineering of T lymphocytes, direct antigen recognition and a capacity for expansion and immune memory that can, in some cases, radically transform the outlook for blood cancers that were previously almost incurable. Results in aggressive B-cell lymphomas and in B-ALL in children and young adults, with high complete remission rates and prolonged survival, have justified marketing authorisations and reimbursement for several CAR-T products, despite high costs and initial uncertainty about long-term effects. In multiple myeloma and other blood cancers, CAR-T cells produce often deep but more transient responses, which underlines that the efficacy and durability of remissions depend on the biology of the disease, the target antigen and the characteristics of the tumour microenvironment.
This therapeutic power comes with specific risks, however, notably cytokine release syndrome, ICANS neurotoxicity, prolonged cytopenias, B-cell aplasia and opportunistic infections, as well as emerging concerns about secondary cancers derived from the modified T lymphocytes. These toxicities, potentially serious but often reversible with rapid and appropriate management, require care organised around qualified centres, intensive monitoring protocols and precise treatment algorithms, including tocilizumab for CRS and high-dose corticosteroids for ICANS. The need for long-term, even lifelong, follow-up to detect late effects and secondary cancers reinforces the importance of real-world registries and international collaboration to fully characterise the safety profile of CAR-T cells.
At the organisational and economic level, CAR-T therapy raises questions of sustainability and fair access, because of its high costs and the concentration of care in specialist centres. Studies show that adopting CAR-T cells generates significant additional hospital costs, but they also suggest that strategies such as outpatient administration, where possible, can reduce the economic burden while maintaining comparable results in safety, efficacy and quality of life. Institutions such as HAS and INCa have responded to these challenges by assessing efficiency, regulating reimbursement, requesting real-world data and working with European partners to improve patient information and accelerate research responsibly.
CAR-T research is booming, with more than 1,500 clinical trials exploring a wide variety of targets, combinations and indications, notably in solid tumours, where the challenges are greater but the rising number of trials reflects strong scientific commitment. Innovations include new-generation CARs, bispecific CARs, and allogeneic, controllable or inhibition-resistant CARs, as well as combinations with other immunotherapies, which could eventually lead to safer, more effective and potentially more accessible products. These developments require rigorous ethical oversight, including truly informed consent, reflection on distributive justice and resource allocation, and inclusion of the patient perspective in regulatory and research decisions.
Overall, CAR-T therapy embodies both the promise and the tensions of precision medicine and immune engineering. It brings hope of cure or prolonged remission when other treatments have failed, but it also introduces new risks, potential inequalities in access and open questions about the very long-term effects of deeply reprogramming the immune system. Continued research, rigorous real-world data collection, constant improvement of care protocols and the active involvement of patients and medical societies will be decisive in turning this promising revolution into a lasting, safe and fair innovation, able to fit into health systems and into the lives of people with blood cancers and perhaps, tomorrow, other complex diseases.
Sources
- A guide to CAR T cell therapies: development, current status and future prospects | Nature Reviews Immunology
- CAR-T cell therapy - Mayo Clinic
- Chimeric antigen receptor — Wikipedia (in French)
- CAR-T cell therapy | EuroGCT (in French)
- Allo-CAR-T cells: a step closer to standardised, accessible cell therapies - Inserm (in French)